Camurus – Talk Bio

Actionable Insights Powered by AI

Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies

4 days ago talkbio0Tagged biotech collaboration, Camurus, cardiometabolic health, Drug Development, eli lilly, FluidCrystal technology, incretin drugs, long-acting therapies, Obesity, pharma partnerships

Eli Lilly; Camurus; obesity drugs; long-acting therapies; FluidCrystal technology; incretin drugs; cardiometabolic health; pharma partnerships; drug development; biotech collaboration

FDA Issues Complete Response Letter to Camurus for Acromegaly Treatment Due to Third-Party Manufacturing Deficiencies

8 months ago talkbio0Tagged Acromegaly, Camurus, Complete, Manufacturer, Response process, United States Food and Drug Administration

FDA, Camurus, Complete Response Letter, Acromegaly, Manufacturing Issues, Third-Party Manufacturer, CAM2029